nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Inflammation—Methylprednisolone—ankylosing spondylitis	0.00678	0.00678	CcSEcCtD
Apraclonidine—Dermatitis contact—Triamcinolone—ankylosing spondylitis	0.00652	0.00652	CcSEcCtD
Apraclonidine—Dermatitis contact—Betamethasone—ankylosing spondylitis	0.00591	0.00591	CcSEcCtD
Apraclonidine—Dermatitis contact—Dexamethasone—ankylosing spondylitis	0.00591	0.00591	CcSEcCtD
Apraclonidine—Dry eye—Dexamethasone—ankylosing spondylitis	0.00553	0.00553	CcSEcCtD
Apraclonidine—Dry eye—Betamethasone—ankylosing spondylitis	0.00553	0.00553	CcSEcCtD
Apraclonidine—Eye pain—Dexamethasone—ankylosing spondylitis	0.00481	0.00481	CcSEcCtD
Apraclonidine—Eye pain—Betamethasone—ankylosing spondylitis	0.00481	0.00481	CcSEcCtD
Apraclonidine—Irritability—Methylprednisolone—ankylosing spondylitis	0.00456	0.00456	CcSEcCtD
Apraclonidine—Inflammation—Methotrexate—ankylosing spondylitis	0.00449	0.00449	CcSEcCtD
Apraclonidine—Irritability—Dexamethasone—ankylosing spondylitis	0.00415	0.00415	CcSEcCtD
Apraclonidine—Irritability—Betamethasone—ankylosing spondylitis	0.00415	0.00415	CcSEcCtD
Apraclonidine—Asthma—Triamcinolone—ankylosing spondylitis	0.00414	0.00414	CcSEcCtD
Apraclonidine—Conjunctivitis—Prednisolone—ankylosing spondylitis	0.0039	0.0039	CcSEcCtD
Apraclonidine—Infestation—Methylprednisolone—ankylosing spondylitis	0.00368	0.00368	CcSEcCtD
Apraclonidine—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.00368	0.00368	CcSEcCtD
Apraclonidine—Bradycardia—Prednisolone—ankylosing spondylitis	0.00367	0.00367	CcSEcCtD
Apraclonidine—Face oedema—Prednisone—ankylosing spondylitis	0.00365	0.00365	CcSEcCtD
Apraclonidine—Irritability—Prednisone—ankylosing spondylitis	0.00361	0.00361	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisolone—ankylosing spondylitis	0.0036	0.0036	CcSEcCtD
Apraclonidine—Conjunctivitis—Triamcinolone—ankylosing spondylitis	0.00359	0.00359	CcSEcCtD
Apraclonidine—Visual impairment—Prednisolone—ankylosing spondylitis	0.00347	0.00347	CcSEcCtD
Apraclonidine—Bradycardia—Triamcinolone—ankylosing spondylitis	0.00337	0.00337	CcSEcCtD
Apraclonidine—Bradycardia—Methylprednisolone—ankylosing spondylitis	0.00336	0.00336	CcSEcCtD
Apraclonidine—Rhinitis—Triamcinolone—ankylosing spondylitis	0.00332	0.00332	CcSEcCtD
Apraclonidine—Rhinitis—Methylprednisolone—ankylosing spondylitis	0.00331	0.00331	CcSEcCtD
Apraclonidine—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.00331	0.00331	CcSEcCtD
Apraclonidine—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.0033	0.0033	CcSEcCtD
Apraclonidine—Pharyngitis—Triamcinolone—ankylosing spondylitis	0.00329	0.00329	CcSEcCtD
Apraclonidine—Conjunctivitis—Dexamethasone—ankylosing spondylitis	0.00325	0.00325	CcSEcCtD
Apraclonidine—Conjunctivitis—Betamethasone—ankylosing spondylitis	0.00325	0.00325	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisolone—ankylosing spondylitis	0.00322	0.00322	CcSEcCtD
Apraclonidine—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.00318	0.00318	CcSEcCtD
Apraclonidine—Erythema—Prednisolone—ankylosing spondylitis	0.00314	0.00314	CcSEcCtD
Apraclonidine—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.00309	0.00309	CcSEcCtD
Apraclonidine—Bradycardia—Dexamethasone—ankylosing spondylitis	0.00306	0.00306	CcSEcCtD
Apraclonidine—Bradycardia—Betamethasone—ankylosing spondylitis	0.00306	0.00306	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—ankylosing spondylitis	0.00302	0.00302	CcSEcCtD
Apraclonidine—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.00301	0.00301	CcSEcCtD
Apraclonidine—Haemorrhage—Betamethasone—ankylosing spondylitis	0.00301	0.00301	CcSEcCtD
Apraclonidine—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.003	0.003	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00298	0.00298	CcSEcCtD
Apraclonidine—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.00296	0.00296	CcSEcCtD
Apraclonidine—Vision blurred—Prednisolone—ankylosing spondylitis	0.00295	0.00295	CcSEcCtD
Apraclonidine—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.00295	0.00295	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisolone—ankylosing spondylitis	0.00291	0.00291	CcSEcCtD
Apraclonidine—Visual impairment—Dexamethasone—ankylosing spondylitis	0.0029	0.0029	CcSEcCtD
Apraclonidine—Visual impairment—Betamethasone—ankylosing spondylitis	0.0029	0.0029	CcSEcCtD
Apraclonidine—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.0029	0.0029	CcSEcCtD
Apraclonidine—Erythema—Triamcinolone—ankylosing spondylitis	0.00288	0.00288	CcSEcCtD
Apraclonidine—Erythema—Methylprednisolone—ankylosing spondylitis	0.00288	0.00288	CcSEcCtD
Apraclonidine—Malaise—Prednisolone—ankylosing spondylitis	0.00283	0.00283	CcSEcCtD
Apraclonidine—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.00282	0.00282	CcSEcCtD
Apraclonidine—Syncope—Prednisolone—ankylosing spondylitis	0.00281	0.00281	CcSEcCtD
Apraclonidine—Eye disorder—Betamethasone—ankylosing spondylitis	0.00281	0.00281	CcSEcCtD
Apraclonidine—Eye disorder—Dexamethasone—ankylosing spondylitis	0.00281	0.00281	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Apraclonidine—Angiopathy—Dexamethasone—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Apraclonidine—Angiopathy—Betamethasone—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Apraclonidine—Arrhythmia—Betamethasone—ankylosing spondylitis	0.00268	0.00268	CcSEcCtD
Apraclonidine—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.00268	0.00268	CcSEcCtD
Apraclonidine—Ill-defined disorder—Triamcinolone—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methylprednisolone—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Apraclonidine—Bradycardia—Prednisone—ankylosing spondylitis	0.00266	0.00266	CcSEcCtD
Apraclonidine—Discomfort—Prednisolone—ankylosing spondylitis	0.00264	0.00264	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisone—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Apraclonidine—Erythema—Betamethasone—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Apraclonidine—Erythema—Dexamethasone—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Apraclonidine—Malaise—Triamcinolone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Apraclonidine—Malaise—Methylprednisolone—ankylosing spondylitis	0.00259	0.00259	CcSEcCtD
Apraclonidine—Syncope—Triamcinolone—ankylosing spondylitis	0.00259	0.00259	CcSEcCtD
Apraclonidine—Syncope—Methylprednisolone—ankylosing spondylitis	0.00258	0.00258	CcSEcCtD
Apraclonidine—Oedema—Prednisolone—ankylosing spondylitis	0.00256	0.00256	CcSEcCtD
Apraclonidine—Myalgia—Triamcinolone—ankylosing spondylitis	0.00245	0.00245	CcSEcCtD
Apraclonidine—Myalgia—Methylprednisolone—ankylosing spondylitis	0.00245	0.00245	CcSEcCtD
Apraclonidine—Eye disorder—Prednisone—ankylosing spondylitis	0.00245	0.00245	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—ankylosing spondylitis	0.00244	0.00244	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—ankylosing spondylitis	0.00244	0.00244	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00243	0.00243	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.00243	0.00243	CcSEcCtD
Apraclonidine—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.00243	0.00243	CcSEcCtD
Apraclonidine—Discomfort—Triamcinolone—ankylosing spondylitis	0.00243	0.00243	CcSEcCtD
Apraclonidine—Discomfort—Methylprednisolone—ankylosing spondylitis	0.00242	0.00242	CcSEcCtD
Apraclonidine—Dry mouth—Triamcinolone—ankylosing spondylitis	0.0024	0.0024	CcSEcCtD
Apraclonidine—Angiopathy—Prednisone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Apraclonidine—Malaise—Betamethasone—ankylosing spondylitis	0.00236	0.00236	CcSEcCtD
Apraclonidine—Malaise—Dexamethasone—ankylosing spondylitis	0.00236	0.00236	CcSEcCtD
Apraclonidine—Oedema—Triamcinolone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Apraclonidine—Syncope—Betamethasone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Apraclonidine—Syncope—Dexamethasone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Apraclonidine—Infection—Triamcinolone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Apraclonidine—Infection—Methylprednisolone—ankylosing spondylitis	0.00233	0.00233	CcSEcCtD
Apraclonidine—Insomnia—Prednisolone—ankylosing spondylitis	0.00231	0.00231	CcSEcCtD
Apraclonidine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.0023	0.0023	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisolone—ankylosing spondylitis	0.0023	0.0023	CcSEcCtD
Apraclonidine—Mental disorder—Prednisone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Apraclonidine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Apraclonidine—Erythema—Prednisone—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Apraclonidine—Myalgia—Dexamethasone—ankylosing spondylitis	0.00223	0.00223	CcSEcCtD
Apraclonidine—Myalgia—Betamethasone—ankylosing spondylitis	0.00223	0.00223	CcSEcCtD
Apraclonidine—Discomfort—Dexamethasone—ankylosing spondylitis	0.0022	0.0022	CcSEcCtD
Apraclonidine—Discomfort—Betamethasone—ankylosing spondylitis	0.0022	0.0022	CcSEcCtD
Apraclonidine—Pain—Prednisolone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Apraclonidine—Vision blurred—Prednisone—ankylosing spondylitis	0.00215	0.00215	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.00214	0.00214	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.00214	0.00214	CcSEcCtD
Apraclonidine—Oedema—Dexamethasone—ankylosing spondylitis	0.00213	0.00213	CcSEcCtD
Apraclonidine—Oedema—Betamethasone—ankylosing spondylitis	0.00213	0.00213	CcSEcCtD
Apraclonidine—Insomnia—Triamcinolone—ankylosing spondylitis	0.00213	0.00213	CcSEcCtD
Apraclonidine—Insomnia—Methylprednisolone—ankylosing spondylitis	0.00212	0.00212	CcSEcCtD
Apraclonidine—Infection—Dexamethasone—ankylosing spondylitis	0.00212	0.00212	CcSEcCtD
Apraclonidine—Infection—Betamethasone—ankylosing spondylitis	0.00212	0.00212	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Apraclonidine—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Apraclonidine—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Apraclonidine—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.0021	0.0021	CcSEcCtD
Apraclonidine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00209	0.00209	CcSEcCtD
Apraclonidine—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00209	0.00209	CcSEcCtD
Apraclonidine—Malaise—Prednisone—ankylosing spondylitis	0.00205	0.00205	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Apraclonidine—Syncope—Prednisone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Apraclonidine—Fatigue—Triamcinolone—ankylosing spondylitis	0.00203	0.00203	CcSEcCtD
Apraclonidine—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Apraclonidine—Pain—Triamcinolone—ankylosing spondylitis	0.00201	0.00201	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—ankylosing spondylitis	0.00198	0.00198	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.00197	0.00197	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00195	0.00195	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00195	0.00195	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—ankylosing spondylitis	0.00194	0.00194	CcSEcCtD
Apraclonidine—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.00194	0.00194	CcSEcCtD
Apraclonidine—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.00193	0.00193	CcSEcCtD
Apraclonidine—Insomnia—Betamethasone—ankylosing spondylitis	0.00193	0.00193	CcSEcCtD
Apraclonidine—Insomnia—Dexamethasone—ankylosing spondylitis	0.00193	0.00193	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00193	0.00193	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.00192	0.00192	CcSEcCtD
Apraclonidine—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.00192	0.00192	CcSEcCtD
Apraclonidine—Paraesthesia—Betamethasone—ankylosing spondylitis	0.00192	0.00192	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—ankylosing spondylitis	0.00192	0.00192	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—ankylosing spondylitis	0.00192	0.00192	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—ankylosing spondylitis	0.0019	0.0019	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Apraclonidine—Oedema—Prednisone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Apraclonidine—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Apraclonidine—Infection—Prednisone—ankylosing spondylitis	0.00185	0.00185	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Apraclonidine—Fatigue—Betamethasone—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Apraclonidine—Fatigue—Dexamethasone—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Apraclonidine—Pain—Betamethasone—ankylosing spondylitis	0.00183	0.00183	CcSEcCtD
Apraclonidine—Pain—Dexamethasone—ankylosing spondylitis	0.00183	0.00183	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00182	0.00182	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.00177	0.00177	CcSEcCtD
Apraclonidine—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.00176	0.00176	CcSEcCtD
Apraclonidine—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.00176	0.00176	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00175	0.00175	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00175	0.00175	CcSEcCtD
Apraclonidine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00173	0.00173	CcSEcCtD
Apraclonidine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00173	0.00173	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—ankylosing spondylitis	0.00172	0.00172	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Dizziness—Prednisolone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Asthenia—Triamcinolone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Apraclonidine—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00168	0.00168	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—ankylosing spondylitis	0.00168	0.00168	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—ankylosing spondylitis	0.00167	0.00167	CcSEcCtD
Apraclonidine—Pruritus—Triamcinolone—ankylosing spondylitis	0.00166	0.00166	CcSEcCtD
Apraclonidine—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00166	0.00166	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Apraclonidine—Dermatitis—Prednisolone—ankylosing spondylitis	0.00161	0.00161	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.00161	0.00161	CcSEcCtD
Apraclonidine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00161	0.00161	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—ankylosing spondylitis	0.0016	0.0016	CcSEcCtD
Apraclonidine—Headache—Prednisolone—ankylosing spondylitis	0.0016	0.0016	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—ankylosing spondylitis	0.0016	0.0016	CcSEcCtD
Apraclonidine—Constipation—Prednisone—ankylosing spondylitis	0.00159	0.00159	CcSEcCtD
Apraclonidine—Dizziness—Triamcinolone—ankylosing spondylitis	0.00156	0.00156	CcSEcCtD
Apraclonidine—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00155	0.00155	CcSEcCtD
Apraclonidine—Infection—Methotrexate—ankylosing spondylitis	0.00154	0.00154	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—ankylosing spondylitis	0.00153	0.00153	CcSEcCtD
Apraclonidine—Asthenia—Dexamethasone—ankylosing spondylitis	0.00153	0.00153	CcSEcCtD
Apraclonidine—Asthenia—Betamethasone—ankylosing spondylitis	0.00153	0.00153	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00152	0.00152	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.00152	0.00152	CcSEcCtD
Apraclonidine—Nausea—Prednisolone—ankylosing spondylitis	0.00152	0.00152	CcSEcCtD
Apraclonidine—Pruritus—Dexamethasone—ankylosing spondylitis	0.00151	0.00151	CcSEcCtD
Apraclonidine—Pruritus—Betamethasone—ankylosing spondylitis	0.00151	0.00151	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—ankylosing spondylitis	0.00151	0.00151	CcSEcCtD
Apraclonidine—Vomiting—Triamcinolone—ankylosing spondylitis	0.0015	0.0015	CcSEcCtD
Apraclonidine—Vomiting—Methylprednisolone—ankylosing spondylitis	0.00149	0.00149	CcSEcCtD
Apraclonidine—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00148	0.00148	CcSEcCtD
Apraclonidine—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00148	0.00148	CcSEcCtD
Apraclonidine—Headache—Triamcinolone—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Apraclonidine—Headache—Methylprednisolone—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Apraclonidine—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00146	0.00146	CcSEcCtD
Apraclonidine—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00146	0.00146	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Apraclonidine—Dizziness—Dexamethasone—ankylosing spondylitis	0.00141	0.00141	CcSEcCtD
Apraclonidine—Dizziness—Betamethasone—ankylosing spondylitis	0.00141	0.00141	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—ankylosing spondylitis	0.00141	0.00141	CcSEcCtD
Apraclonidine—Nausea—Triamcinolone—ankylosing spondylitis	0.0014	0.0014	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—ankylosing spondylitis	0.0014	0.0014	CcSEcCtD
Apraclonidine—Nausea—Methylprednisolone—ankylosing spondylitis	0.00139	0.00139	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00139	0.00139	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—ankylosing spondylitis	0.00138	0.00138	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00137	0.00137	CcSEcCtD
Apraclonidine—Vomiting—Dexamethasone—ankylosing spondylitis	0.00136	0.00136	CcSEcCtD
Apraclonidine—Vomiting—Betamethasone—ankylosing spondylitis	0.00136	0.00136	CcSEcCtD
Apraclonidine—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Dermatitis—Betamethasone—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Headache—Betamethasone—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Headache—Dexamethasone—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—ankylosing spondylitis	0.00133	0.00133	CcSEcCtD
Apraclonidine—Pain—Methotrexate—ankylosing spondylitis	0.00133	0.00133	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—ankylosing spondylitis	0.00132	0.00132	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.00128	0.00128	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—ankylosing spondylitis	0.00127	0.00127	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.00127	0.00127	CcSEcCtD
Apraclonidine—Nausea—Dexamethasone—ankylosing spondylitis	0.00127	0.00127	CcSEcCtD
Apraclonidine—Nausea—Betamethasone—ankylosing spondylitis	0.00127	0.00127	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—ankylosing spondylitis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00123	0.00123	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—ankylosing spondylitis	0.00118	0.00118	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—ankylosing spondylitis	0.00117	0.00117	CcSEcCtD
Apraclonidine—Headache—Prednisone—ankylosing spondylitis	0.00116	0.00116	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00114	0.00114	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—ankylosing spondylitis	0.00111	0.00111	CcSEcCtD
Apraclonidine—Nausea—Prednisone—ankylosing spondylitis	0.0011	0.0011	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—ankylosing spondylitis	0.0011	0.0011	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—ankylosing spondylitis	0.00106	0.00106	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—ankylosing spondylitis	0.00103	0.00103	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—ankylosing spondylitis	0.000988	0.000988	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—ankylosing spondylitis	0.000979	0.000979	CcSEcCtD
Apraclonidine—Headache—Methotrexate—ankylosing spondylitis	0.000973	0.000973	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—ankylosing spondylitis	0.000923	0.000923	CcSEcCtD
